Healthcare Volatile Stocks: Pharmacyclics (NASDAQ:PCYC), Organovo Holdings (NYSEMKT:ONVO), Zogenix (NASDAQ:ZGNX), Baxano Surgical (NASDAQ:BAXS)

Pharmacyclics, Inc. (NASDAQ:PCYC) announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Pharmacyclics, Inc. (NASDAQ:PCYC) shares after opening at $103.43 moved to $103.44 on last trade day and at the end of the day closed at $93.26. Company price to sales ratio in past twelve months was calculated as 26.58 and price to cash ratio as 10.88. Pharmacyclics, Inc. (NASDAQ:PCYC) showed a negative weekly performance of -8.46%.

On April 10, 2014, Organovo Holdings, Inc. (NYSEMKT:ONVO) released the information to update investors on the results of its initial study of 3D breast tissues generated with its NovoGen MMX Bioprinter in breast cancer models. Organovo Holdings Inc. (NYSEMKT:ONVO) shares fell -8.08% in last trading session and ended the day on $7.74. ONVO return on equity ratio is recorded as -134.90% and its return on assets is -113.60%. Organovo Holdings Inc. (NYSEMKT:ONVO) yearly performance is 107.51%.

On 8 April Zogenix Inc. (NASDAQ:ZGNX) presented its case in U.S. District Court in Boston requesting an immediate order staying the ban on the U.S. Food and Drug Administration (FDA)-approved prescription drug product, Zohydro™ ER (hydrocodone bitartrate) extended-release capsules (CII), entered on March 27, 2014, by Massachusetts Governor Deval Patrick. Zogenix appreciates the opportunity to be heard by the court on an expedited basis. A follow-up hearing has been scheduled for Monday, April 14, 2014. Zogenix, Inc. (NASDAQ:ZGNX) shares moved down -8.90% in last trading session and was closed at $2.56, while trading in range of $2.51 – $2.83. Zogenix, Inc. (NASDAQ:ZGNX) year to date (YTD) performance is -25.58%.

Baxano Surgical, Inc. (NASDAQ:BAXS), a medical device company focused on designing, developing and marketing minimally invasive products to treat degenerative conditions of the lumbar spine, yesterday announced that it has received U.S. Food and Drug Administration 510(k) clearance (k133743) of its Avance™ MIS Pedicle Screw System, which may be used as an adjunct to fusion in numerous degenerative and complex spinal pathologies. Baxano Surgical Inc. (NASDAQ:BAXS) weekly performance is 8.57%. On last trading day company shares ended up $1.14. Baxano Surgical Inc. (NASDAQ:BAXS) distance from 50-day simple moving average (SMA50) is -8.70%. Analysts mean target price for the company is $3.55.